To assess changes in bone mineral density (BMD) and trabecular bone score (TBS) in peri-/postmenopausal women with osteoporosis following Osteostrong® intervention over 12 months.
Key Findings:
Significant increases in lumbar spine BMD in group G2 (0.029 g/cm2, Bonferroni-adjusted p < 0.001) and G4 (0.025 g/cm2, Bonferroni-adjusted p = 0.05).
Modest improvements in total hip BMD left in group G2 (0.028 g/cm2, Bonferroni-adjusted p = 0.05).
Other changes in femoral neck BMD, total hip BMD, and TBS were not significant after Bonferroni correction.
Interpretation:
The Osteostrong® intervention showed modest improvements in lumbar spine BMD, with some subgroup effects being significant but requiring cautious interpretation due to Bonferroni adjustments and study limitations.
Limitations:
The study's quasi-experimental design limits causal inferences.
Small sample sizes in subgroups may affect the reliability of findings.
Lack of a randomized controlled trial design may introduce biases.
Conclusion:
Further randomized trials are warranted to confirm the efficacy of Osteostrong® in improving BMD in postmenopausal women with osteoporosis.
As osteoporosis treatment continues to evolve, clinicians are moving beyond bone mineral density scores alone and placing greater emphasis on fracture risk when making therapeutic decisions
A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness
